| 5.03 -0.21 (-4.01%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.41 | 1-year : | 7.48 |
| Resists | First : | 5.48 | Second : | 6.41 |
| Pivot price | 4.69  |
|||
| Supports | First : | 4.49 | Second : | 3.88 |
| MAs | MA(5) : | 5.16 |
MA(20) : | 4.56 |
| MA(100) : | 6.88 |
MA(250) : | 5.26 |
|
| MACD | MACD : | 0 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 78.7 |
D(3) : | 83.5 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 13.5 | Low : | 2.27 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CLNN ] has closed below upper band by 29.7%. Bollinger Bands are 49.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.16 - 5.18 | 5.18 - 5.2 |
| Low: | 4.73 - 4.77 | 4.77 - 4.79 |
| Close: | 4.98 - 5.03 | 5.03 - 5.08 |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Sat, 28 Feb 2026
CLNN Should I Buy - Intellectia AI
Tue, 24 Feb 2026
Clene (CLNN) Outlines Key Developments for CNM-Au8 in 2026 - GuruFocus
Tue, 24 Feb 2026
Experimental ALS drug CNM-Au8 heads toward 2026 FDA review - Stock Titan
Fri, 20 Feb 2026
Option grant gives Clene (NASDAQ: CLNN) director 5,372 share rights - Stock Titan
Thu, 19 Feb 2026
ALS and MS-focused biopharma Clene to give virtual update to investors - Stock Titan
Tue, 17 Feb 2026
When Will Clene Inc. (NASDAQ:CLNN) Turn A Profit? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 7.27e+006 (%) |
| Held by Institutions | 28.6 (%) |
| Shares Short | 517 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.27e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -37 % |
| Return on Assets (ttm) | 653.3 % |
| Return on Equity (ttm) | -56.3 % |
| Qtrly Rev. Growth | 214000 % |
| Gross Profit (p.s.) | -121.77 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 258824 |
| Qtrly Earnings Growth | -3.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.83 |
| Dividend | 0 |
| Forward Dividend | 821960 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|